Pacific Biosciences of California, Inc. (PACB)
PacBio Q4 Earnings and Revenues Beat Estimates, Gross Margin Up
PACB beats Q4 estimates as revenue jumps 14%, gross margin hits 41% and 2026 revenues are projected in the range of $165-$180M after strategic moves.
Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.2 per share a year ago.
Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $2.26, indicating a -4.64% shift from the previous trading day.
PacBio: The Consumables Flywheel Is Turning. The Chart Wants Confirmation
Pacific Biosciences is transitioning to a recurring revenue model as consumables reach a record 55% of Q3 revenue, driving margin improvements. Non-GAAP gross margin hit 42% in Q3, with management attributing gains to a favorable mix shift and yield improvements, notably from multi-use SMRT Cells. Cash burn is materially lower, with year-end cash at $279.5M and Q3 burn around $16M, supporting the company's path toward self-funding.
Pacific Biosciences of California (PACB) Stock Dips While Market Gains: Key Facts
Pacific Biosciences of California (PACB) closed the most recent trading day at $2.58, moving 3.37% from the previous trading session.
PacBio Stock Up on HiFi Sequencing Adoption for Major SUDC Research
PACB stock jumps as HiFi whole-genome sequencing becomes first-line in major SUDC research, highlighting adoption momentum.
Pacific Biosciences of California, Inc. (PACB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Pacific Biosciences of California, Inc. (PACB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PacBio Stock Dips Post Latest Launch to Expand Multiomics Capabilities
PACB introduces CiFi, a new sequencing method designed to expand multiomics capabilities without added hardware.
Here's Why You Should Add PacBio Stock to Your Portfolio
PACB is gaining from product development and strong Q3 results, with Revio and Vega driving growth, though longer purchasing cycles remain a risk.
Three Genomics Stocks Worth Tracking This Year
Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.
Pacific Biosciences (PACB) Upgraded to Buy: Here's Why
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PACB Stock Down Despite Q3 Earnings Beat Estimates, Revenues Down Y/Y
PacBio posts a narrower Q3 loss and margin gains, but shares fall as revenues dip amid softer instrument demand.
